These three stocks, which are at or near the top of their respective industries, just increased dividends by double-digit percentages. Below, I’ll reveal how much these companies are paying out to shareholders now. I’ll also touch on notable share buyback news. Plus, I’ll provide an update on key proposed legislation that investors should be aware of regarding one of these companies. Get Mastercard alerts:PACCAR: +4% Yield Makes It One of the Top Dogs for Industrial Dividends PACCAR Dividend PaymentsDividen ...

Novo Nordisk stock crashed 17% on Friday after revealing disappointing trial results.In this video, I will cover the recent updates regarding Novo Nordisk (NVO -17.83%) and whether or not the dip is worth buying over Eli Lilly (LLY 1.35%). Watch the short video to learn more, consider subscribing, and click the special offer link below.*Stock prices used were from the trading day of Dec. 20, 2024. The video was published on Dec. 22, 2024. ...

Eli Lilly and Company (LLY) announced that the FDA has approved its popular obesity drug, Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. OSA is a common sleep-related breathing disorder that causes repeated interruptions in breathing (apnea) or shallow breathing (hypopnea) during sleep. OSA marks the second indication for Zepbound. The drug was approved to treat obesity or overweight issues in November 2023.With the approval, Zepbound becomes the ...

Eli Lilly (LLY 1.35%) soared more than 60% from the start of the year through its peak this summer, thanks to the company's dominance in one of today's most in-demand areas: the obesity drug market. Lilly sells tirzepatide, a compound sold for weight loss under the name Zepbound and for type 2 diabetes under the name Mounjaro. But doctors have prescribed either one to patients trying to shed pounds, and both have become blockbusters.These drugs have helped the big pharma player report double-digit quarterly ...

Investing in dividend stocks is a great strategy for many reasons, including the potential they offer you to significantly boost your long-term returns by automatically reinvesting their payouts. Furthermore, the pursuit of dividends need not come at the expense of other investment styles. Some income stocks look like excellent growth stocks, too.Here are two examples: Microsoft (MSFT -0.10%) and Eli Lilly (LLY 1.35%). These two market leaders are popular on Wall Street. Take Israel "Izzy" Englander, the fo ...

Since Eli Lilly reported third-quarter earnings on Oct. 30, its shares have had a prolonged sell-off.Since pharmaceutical giant Eli Lilly (LLY 1.35%) reported earnings for the third quarter on Oct. 30, shares have been punished by investors. As of this writing, Lilly's stock price has plunged as much as 14% since Q3 earnings, and it's currently trading 6% lower than it was prior to the report.This precipitous sell-off has placed Lilly stock near its lowest levels in six months. Below, I'll explore what's be ...

ToplineThe Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound approved as a weight-loss drug last year.A sign for Eli Lilly & Co. stands outside their corporate headquarters in Indianapolis on April 26, ... [+] 2017.Copyright 2017 The Associated Press. All rights reserved. Key FactsZepbound, an Eli Lilly drug, can now be prescribed to adults with “moderate-to-severe obst ...

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, the drugmaker announced Friday, expanding its use and possibly its insurance coverage in the U.S.The weekly injection is now cleared for patients with obesity and moderate-to-severe obstructive sleep apnea, which refers to ...

 Averaging up to 20% of weight loss, adults taking Zepbound had at least 25 fewer breathing interruptions each hour as they slept Up to 50% of adults taking Zepbound no longer had symptoms associated with OSA after one year INDIANAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obe ...

Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.Bad news for Novo Nordisk (NVO -17.34%) Friday was good news for Eli Lilly (LLY 4.92%) and Viking Therapeutics (VKTX 6.33%), its two main rivals in the field of weight loss drugs. This morning, Novo reported headline results from its phase 3 trial of a new weight loss drug, CagriSema, and while objectively not bad, the results were less great than Novo was shooting for.As of 11:05 a.m. ET, Novo Nordisk stock is down a dis ...